Unlock the promise of gene therapy and gene editing
Gene Therapy R&D Solutions
Benchling’s Gene Therapy R&D Solutions are trusted by leading gene therapy innovators to accelerate their R&D. The Solutions enable scientists to study gene editing and gene therapy technologies at scale with improved productivity, intuitive collaboration, and contextual insights. Our modern, digital solutions combine the capabilities of traditional ELN, LIMS, and molecular biology tools in a unified cloud solution that natively supports gene therapy R&D.
The Gene Therapy R&D Accelerators provide best practices that shorten time-to-value for research and process development. The Accelerators contain:
Data model – entity relationship diagram (ERD) which serves as an implementation blueprint
Tenant configuration – pre-defined tenant configuration using templates and dashboards for registering entities, tracking results, increasing inventory utilization, and streamlining workflows
Solution Guide – highlight capabilities and latest product features
Benchling’s services support customers from implementation through ongoing success.
Professional Services – solution-specific domain expertise to jumpstart your optimal implementation
Customer Success – continual solution optimization that takes advantage of new feature releases and ongoing industry learning
See Benchling's Gene and Cell Therapy R&D Solutions in action
How we deliver
Dedicated expertise
Our Customer Experience professionals possess deep scientific expertise, as well as training on information technology best practices. They apply this know-how to support gene therapy customers across a wide range of R&D teams.
Continuous oversight
Leverage Benchling's pre-implementation solutions consulting, professional implementation services, and customer success management expertise to help you get the most out of Benchling.
Focused R&D Support
Take advantage of Benchling’s foundational implementation guides, developed by our Customer Experience team to support many gene therapy R&D functions, including:
Target discovery
CRISPR gene editing
Viral production
Powering breakthroughs for over 1,200 biotechnology companies, from startups to Fortune 500s